Cirrhosis-Specific Oral Nutrition Market Expected to Reach $553.3 Million by 2036

This growth is largely driven by the increasing demand for nutritionally measured oral products to meet the protein and energy needs of patients with cirrhosis. According to the 2026 KASL guideline, recommendations include 30 to 35 kcal/kg per day and 1.2 to 1.5 g/kg of protein, along with late-evening snacks. High-protein, high-energy oral nutritional supplements (ONS), branched-chain amino acid (BCAA) supplements, and late-evening snacks are becoming essential components of daily nutrition plans for these patients.

The market's growth is also supported by a shift to premium-grade products characterized by energy-dense compositions and convenient, ready-to-drink (RTD) formats. Regional purchasing preferences vary; for instance, the USA tends to rely on hospital-based initiation, while other countries like the UK and Germany focus on listed medical uses.

In terms of product type in 2026, high-protein high-energy ONS are expected to hold a significant share, accounting for 37.7% of total revenue. The metabolic or MASLD segment is projected to capture 46.8% of revenue, highlighting the intertwined needs for managing cirrhosis and associated metabolic conditions. The RTD product form is anticipated to constitute 49.8% of the market revenue due to its ease of use.

Homecare is expected to generate 43.7% of end-user revenue in 2026, as cirrhosis patients consistently use oral nutritional products at home post-discharge. Hospital pharmacies are projected to account for 36.3% of sales channel revenue, as they serve as the primary source for initiating nutrition support for patients prior to leaving the hospital.

However, the market faces challenges such as poor tolerance and taste of some products, which can hinder repeat usage. Compact, ready-to-use nutrition products offer potential growth opportunities by streamlining consumption and improving adherence.

Country-specific growth rates reflect varying healthcare practices, with South Korea projected to grow at a 7.4% CAGR, surpassing the USA at 6.8% and the UK at 6.5%.

Key players in the market include Abbott, Otsuka Pharmaceutical, Nestlé Health Science, Danone Nutricia, Fresenius Kabi, Ajinomoto, Victus, and Medtrition, which are focused on enhancing their portfolios to better cater to the needs of cirrhosis patients.